

1 **A preliminary study in Wistar rats with enniatin A contaminated feed.**

2

3 EN A test in vivo

4 L. Manyes*, L. Escrivá, A.B. Serrano, Y. Rodríguez-Carrasco, J. Tolosa, G. Meca, G. Font

5 Laboratory of Food Chemistry and Toxicology, Faculty of Pharmacy, University of
6 Valencia, Av. Vicent Andrés Estellés s/n, 46100 Burjassot, Spain

7

8

9

10

11

12

13

14

15

16 *Corresponding author:

17 Lara Manyes

18 *Laboratory of Food Chemistry and Toxicology, Faculty of Pharmacy*

19 *University of València*

20 *Av. Vicent Andrés Estellés s/n*

21 *46100 Burjassot,*

22 *Spain*

23

24 e-mail: lara.manyes@uv.es

25 Telephone: +34963544958, Fax: +3496354954

26

27

28

29

1 **Abstract**

2 A 28-day repeated dose preliminary assay, using **enniatin A** naturally contaminated feed
3 through microbial fermentation by a *Fusarium tricinctum* strain, was carried out employing
4 two months-old female Wistar rats as *in vivo* experimental model. In order to simulate a
5 physiological test of a toxic compound naturally produced by fungi, five treated animals
6 were fed during twenty-eight days with fermented feed. As control group, five rats were fed
7 with standard feed. At the 28th day, blood samples were collected for biochemical analysis
8 and the gastrointestinal tract, liver and kidneys were removed from each rat for **enniatin A**
9 detection and quantitation. Digesta were collected from stomach, duodenum, jejunum,
10 ileum and colon. **Enniatin A** present in organs and in biological fluids was analyzed by
11 liquid chromatography-diode array detector (LC-DAD) and confirmed by LC-mass
12 spectrometry linear ion trap (MS-LIT); also several serum biochemical parameters and a
13 histological analysis of the duodenal tract were performed. No adverse effect was found in
14 any treated rat at the EN A concentration (20.91 mg/kg bw/day) tested during the 28-day
15 experiment. EN A quantitation in biological fluids ranged from 1.50 to 9.00 mg/kg,
16 whereas in the gastrointestinal organs the EN A concentration ranged from 2.50 to 23.00
17 mg/kg. The high EN A concentration found in jejunum liquid and tissue points to them as
18 an absorption area. Finally, two EN A degradation products were identified in duodenum,
19 jejunum and colon content, probably produced by gut microflora.

20 **Keywords:** Enniatin A, *Fusarium tricinctum*, *in vivo* study, LC-DAD, LC-MS-LIT,

21
22
23
24

1 **1. Introduction**

2 Enniatins (ENs) are secondary fungal metabolites that have been known for several decades
3 (Ivanova et al., 2006). Chemically there are six-membered cyclic depsipeptides, which are
4 commonly composed of three D- α -hydroxyisovaleric acid (Hiv) residues linked
5 alternatively to three L-configured N-methyl amino acid residues to give an 18-membered
6 cyclic skeleton (Zhukhlistova et al., 1999). ENs are produced by strains of several species
7 of fungal genera as *Alternaria*, *Fusarium*, *Halosarpheia* and *Verticillium* (Supothina et al.,
8 2004). ENs produced by *Fusarium subglutinans*, *Fusarium proliferatum* and *Fusarium*
9 *tricinctum* are cereals contaminants, especially maize and its derivatives. ENs have been
10 found as worldwide natural contaminants of several food and feed products (Jestoi, 2008). A
11 few years ago, Meca et al. (2010a) have reported ENs contamination of cereals available in
12 the Spanish market and their levels ranged from 0.51 to 11.78 mg/kg.

13 ENs possess a wide range of biological activities: these substances are known as
14 ionophores, phytotoxins, anthelmintic and antibiotics compounds (Jestoi, 2008). ENs
15 antibiotic effects have been used in a pharmaceutical commodity with anti-inflammatory
16 properties called fusafungine (Akbas et al., 2004). There are applications for ENs in
17 respiratory tract infections treatment and it has been reported a positive effect on wound
18 healing after tonsillectomy (Akbas et al., 2004). Several studies have indicated that ENs
19 change the monovalent ion transport across membranes and disrupt the ionic selectivity of
20 cell walls. This effect is particularly debilitating in mitochondrial membranes, resulting in
21 the uncoupling of oxidative phosphorylation (Tonshin et al., 2010).

22 Several studies have evaluated the ENs cytotoxic activity *in vitro* using as experimental
23 model rodent, monkey, porcine, insect and human cell lines (Fornelli et al., 2004; Vongvilai

1 et al., 2004; Ivanova et al., 2006; Jestoi, 2008; Lee et al., 2008; Behm et al., 2009;
2 Dornetshuber et al., 2009; Hyun et al., 2009; Watjen et al., 2009; Meca et al., 2010b, 2011).
3 In the scientific literature, only few studies related to the ENs toxicity *in vivo* are available.
4 In particular, Bosch et al. (1989) studied the toxicity of ENs, among other mycotoxins, in
5 *Fusarium* contaminated feed on twenty day old white female Spargue Dawley rats,
6 evidencing no toxic signs. To be sure about which mycotoxins were responsible of the
7 effects, they administrated a mixture of ENNs in single oral dose (0.05 mg/g body weight
8 (bw)). McKee et al. (1997) studied a hypothetical ENs property to reduce the human
9 immunodeficiency virus (HIV) growth using the hollow fiber assay and employing mice as
10 biological model. They used an ENs A1, B and B1 purified mixture (from 1.25 to 40
11 mg/kg) injected intraperitoneally every 8h during 6 days. Any anti-HIV properties were not
12 found but 40, 20 and 10 mg/kg doses were lethal.

13 Considering the lack of information in physiological conditions related to the ENs toxicity
14 *in vivo*, the aims of this research were: a) to study the EN A *in vivo* potential toxicity trough
15 a repeated dose assay using standard rat feed contaminated by a microbial fermentation of
16 *Fusarium tricinctum* strain; b) to evaluate the EN A presence in several rat organs after a 28-
17 day continuous ingest and c) to identify possible EN A degradation products from gut
18 microflora.

19

20 **2. Materials and methods**

21 2.1 Chemicals

22 Acetonitrile, methanol, and ethyl acetate were purchased from Fisher Scientific (Madrid,
23 Spain). Deionized water (<18 M Ω cm⁻¹ resistivity) was obtained from a Milli-Q water
24 purification system (Millipore, Bedford, MA, USA). Chromatographic solvents and water

1 were degassed for 20 min using a Branson 5200 ultrasonic bath (Branson Ultrasonic Corp.,
2 CT, USA). Potato dextrose broth (PDB) was obtained from Insulab (Valencia, Spain).
3 Phosphate Buffered Saline (PBS), glycerol and ENs A standard solution stock (purity: 99%
4 molecular weight 682.92 g/mol) were purchased from Sigma Aldrich (Madrid, Spain).

5 2.2. Strain and culture conditions for the ENs production on rat feed

6 A solid medium represented by the rat feed (Autoclaved Harlan lab blocks, Castellar del
7 Vallés, Spain) was utilized in this study. The medium was prepared weighting 5 kg in two
8 2.5 L Erlenmeyer flasks and autoclaved at 121°C during 20 min. Each one was inoculated
9 with 25 ml of a conidia suspension (10^6 conidia/ml sterile water) of *Fusarium tricinctum*
10 CECT 20232 in PDB. Conidial concentration was measured by optical density at 600 nm in
11 sterile water and adjusted to 10^6 conidia/ml PDB as reported Kelly et al. (2006).

12 *F. tricinctum* CECT 20232 strain was obtained from the Spanish Type Culture (CECT
13 Valencia, Spain), in sterile 18% glycerol. Fermentations were carried out at 25°C on an
14 orbital shaker (IKA Ks 260 basic, Stanfen, Germany) in batch culture for 30 days. At the
15 end of fermentations, the solid culture was autoclaved at 121°C during 20 min to promote
16 fungi inactivation, and after drying and milling, ENs analysis was done.

17

18 2.3 ENs extraction from rat feed

19 A modified method based on Chelkowski et al. (2007) for mycotoxins extraction was
20 performed. Briefly, ENs contained in fifteen grams of dried contaminated feed were
21 extracted with 100 ml methanol–water mixture (75:25) using an Ika T18 basic Ultraturrax
22 (Staufen, Germany) for 5 min. Samples were then filtered through Phenomenex No. 4 filter
23 paper (Torrance, CA, USA) and thereafter the solvent was removed under reduced

1 pressure. Each extract was dissolved in 5 ml of methanol and filtered through a 0.22 µm
2 filter Phenomenex before toxin identification and quantitation by liquid chromatography
3 (LC)-DAD as reported by Meca et al. (2010a) (see 2.8).

4 2.4 *In vivo* study design

5 Ten female Wistar rats (average body weight: 250 g) were acquired from Pharmacy animal
6 facility (Universitat de València, Spain). The Institutional Animal Care and Use Committee
7 of the University of Valencia approved all animal procedures (protocol n°
8 A1338818442265). Animals were divided in two groups: 5 rats in the control group and 5
9 in the treated one. Each group was housed in one cage in a windowless room with a 12h
10 light-dark cycle. The study rooms were maintained under controlled conditions appropriate
11 for the species (temperature 22°C, relative humidity 45-65%). After 7 days of adaptation,
12 the control group was fed with the Harlan autoclaved lab box feed, while the test group was
13 fed with EN A contaminated feed (see 2.2). Treatment was maintained for 28 days in order
14 to simulate a preliminary subchronic study to be able to analyze EN A distribution. The
15 body weight of each rat was controlled weekly using a weighing scale. Rats were sacrificed
16 by isoflurane gas asphyxiation and blood samples were collected via cardiac puncture.
17 Blood samples were allowed to clot for 30 min and then the serum layer was separated by
18 centrifugation at 1000 rpm for 30 min at 4°C. Serum was kept at -20°C until analysis. The
19 gastrointestinal tract (from stomach to rectum) was removed from all rats and digesta were
20 collected from stomach, duodenum, jejunum, ileum and colon. Digesta collection of the
21 intestinal compartments was carried out flushing the tissues with 1 ml PBS twice. Also the
22 liver, kidneys, heart, thymus and spleen of each animal were recollected after terminal

1 sacrifice (Figure 1). Each organ collected was weighted for further comparison between the
2 treated and the control animals.

3 2.5 Histological and biochemical analysis

4 Histological analyses of duodenum tissue from treated and control rats, focused on
5 enterocytes atrophy determination and on the presence of cells liquid in the gut tissue, were
6 carried out by Echevarne laboratory (Barcelona, Spain). Duodenum tissue samples were
7 fixed in formaldehyde (40% v/v in water), embedded in paraffin, sectioned at 4 μm and
8 stained with haematoxylin and eosin before analysis. Biochemical parameters analyzed in
9 serum were: bile salts, glutamic-pyruvic transaminase, glutamic-oxaloacetic transaminase,
10 total bilirubin, cholesterol, alkaline phosphatase, gamma-glutamyl transpeptidase and urea
11 through ELISA kit analysis (Echevarne laboratory, Barcelona, Spain).

12 2.6 EN A surrogate recovery

13 Each tissue (0.5 g) and digest (0.5 ml) was placed in a 15 ml plastic test tube and fortified
14 with 5 μl of EN A at 1000 ppm. 30 min after spiking, each sample was extracted with 1 ml
15 of ethyl acetate using a vortex VWR international (Barcelona, Spain) for 3 min. Then,
16 mixtures were centrifuged at 4000 rpm and at 4°C during 15 min (Centrifuge 5810R,
17 Eppendorf, Germany). Organic phases were collected into new tubes. Ethyl acetate
18 addition, vortex, centrifugation and collection steps were repeated three times. The extracts
19 were then evaporated dryness under nitrogen flow at 30°C and reduced pressure (5 psi), in
20 order to accelerate organic phase evaporation by decreasing the partial vapor pressure of
21 the solvent just above the liquid surface (Turbovap LV, Zymark, Runcorn, UK). Dried
22 samples were resuspended in 1 ml of methanol and filtered with a 0.22 μm filter
23 (Phenomenex, Madrid, Spain) prior to their LC analysis.

1 2.7 EN A extraction from intestinal fluids

2 EN A contained in the stomach and intestinal fluids were extracted according to Meca et al.
3 (2012). One milliliter of each intestinal fluid was placed in a 15 ml test tube, and extracted
4 with 2 ml of ethyl acetate using a vortex VWR international (Barcelona, Spain) for 3 min.
5 Following steps were performed as described in section 2.6.

6 2.8 EN A extraction from tissues

7 EN A contained in the tissues collected from control and treated rats was extracted as
8 follows: 0.5 g of each tissue was introduced in a 15 ml plastic tube and 2 ml of PBS (1X,
9 pH 7.5) was added. Sample were completely grounded using an Ultraturrax T8 IKA
10 (Staufen, Germany) during 3 min. EN A was extracted from the PBS solution using 4 ml of
11 ethyl acetate employing a vortex (VWR international, Barcelona, Spain) during 3 min.
12 Following steps were performed as described in section 2.6.

13 2.9 LC-DAD analysis

14 LC analyses of EN A (Meca et al., 2010a) were performed using LC-10AD pumps and a
15 diode array detector (DAD) (Shimadzu, Japan). A Gemini (150 x 4.6 mm, 5 μ m)
16 Phenomenex column was used. LC conditions were set up using a constant flow at 1.0
17 ml/min of acetonitrile–water (70:30 v/v) as starting eluent system. The starting ratio was
18 kept constant for 5 min and then it was linearly modified to 90% acetonitrile in 10 min.
19 After 1 min the mobile phase was set to the initial conditions in 4 min. All samples were
20 filtered through a 0.22 μ m syringe filter Phenomenex prior to injection (20 μ L) into the
21 column. EN A was detected at 205 nm. Mycotoxin identification was performed by
22 comparing retention times and UV spectra of samples with those of pure standards. A
23 further confirmation action was performed by co-injecting pure standards together with

1 each sample. Mycotoxin quantitation was determined by comparing tested samples peak
2 areas with a calibration curve performed with standards (n=4).

3 2.10 LC-MS-Linear Ion Trap (LIT) confirmation

4 An applied Biosystems/AB SCIEX QTRAP® linear ion traps mass spectrometer (Concord,
5 Ontario, Canada), coupled to a Turbo Ion Spray source was used. This instrument is based
6 on a triple-quadrupole path (QqQ) in which the third quadrupole can also be operated as a
7 linear ion trap (QqLIT) with improved performance. In the QqLIT configuration the Q
8 TRAP can also operate in enhanced resolution scan (ER) and in enhanced product ion scan
9 (EPI) modes. Applied Biosystem/MDS SCIEX Analyst software version 1.3.2 was used for
10 data acquisition and processing.

11 A Gemini (150 x 2.0 mm, 5 µm) Phenomenex column was used. LC was set using a
12 constant flow of 0.2 ml/min of acetonitrile/water (70:30 v/v) with 0.1 % of HCOOH
13 isocratically. The instrument was operated in the positive ion electrospray mode using the
14 following parameters: cone voltage 40 V, capillary voltage 3.80 kV, source temperature
15 350°C, desolvation temperature 270°C and collision gas energy 5 eV. EN A identification
16 and quantitation was performed using the modality of ER, utilizing the mass range from
17 700 to 900 Da. The utilization of the mass spectrometry associated to a linear ion trap
18 permitted to obtain an enhanced characterization of the isolated compounds.

19 2.11 Mass spectrometry characterization of the EN A degradation products

20 Characterization of the newly formed compounds was performed as explained in 2.10 using
21 the LC coupled to LIT in ER mode.

22

23

1 2.12 Calculations

2 Recoveries of fortified tissues and biological fluid samples were calculated as the
3 percentage of the EN A detected amount related to the total EN A spiked in each of them.

4 Recovery studies were performed in triplicate and the spiking levels were 1.0, 5.0 and 10
5 $\mu\text{g/g}$.

6 For the treated rats liquid contents and tissues, the absolute amount of mycotoxins (mg)
7 was calculated by multiplying the measured sample volume or weight by the EN A
8 concentration found.

9 **3. Results and discussion**

10 3.1. Method performance

11 Mean recovery of fortified tissues and biological fluid samples ($n = 3$) at 3 levels of EN A
12 (1.0, 5.0 and 10 $\mu\text{g/g}$), was of 97.8% (range= 70-156%) with a relative standard deviations
13 of 3.5% (range= 1.5-5.5%). Intra-day ($n= 5$) and inter-day (5 different days) precision were
14 2.4% and 9.0%, respectively. These values were below $\pm 10\%$ which is the maximum
15 variation for certification exercises for several mycotoxins (2002/657/EC). The limit of
16 detection (LOD) and the limit of quantitation (LOQ) calculated as signal to noise ratio, S/N
17 = 3 and $S/N = 10$, were 0.2 and 0.6 $\mu\text{g/g}$ respectively (Table 1).

18 3.2 EN A quantitation of contaminated feed

19 Feed contamination by fungi strain was carried out in order to reproduce experimentally the
20 natural mycotoxin presence in a food matrix. *Fusarium tricinctum* strain CECT 2032,
21 through microbial fermentation, produced the mycotoxin in rat feed. In figure 2a is shown
22 the LC-MS-LIT chromatogram of the EN A detected at 465 mg/kg in the contaminated
23 feed. Moreover, in figure 2b is evidenced the MS-LIT spectrum of the bioactive compound

1 EN A, with three characteristic signals that identify the structure of this bioactive
2 compound as the molecular weight (MW=682.92 g/mol), the sodium and the potassium
3 adduct. The EN A identification was also confirmed by the comparison of the retention
4 time (RT=27.61 min) of the EN A standard solution with the peak of the EN A present in
5 the sample.

6 3.3 EN A distribution in rat tissues and biological fluids

7 This study was designed as a 28-day repeated dose assay in rats using the bioactive
8 compound EN A. Ten 2 months-old female Wistar rats were divided in two groups (treated
9 and control), five in each cage. During 28 days, the treated group was fed *ad libitum* with
10 the EN A contaminated feed whereas the control group was fed simultaneously with
11 standard feed.

12 Rats were observed and weighted weekly (Table 2a). First weight measure was taken on
13 day 0 and, the last measure was obtained, the sacrifice day. As none of them showed
14 significant weight gain or loss, it was assumable that all of them ate a similar amount of
15 feed during the assay. Considering that each animal consumed daily approximately 11.82 g
16 of contaminated feed, the EN A daily intake was of 5.50 mg/per rat. Finally, considering
17 that the mean weight of the treated animals was 263.48 g (Table 2a), the EN A daily intake
18 was 20.91 mg/kg bw/day.

19 After the animals terminal sacrifice, they were examined and neither visible weight nor
20 morphological tissue or organ changes were observed (Table 2b). The histological analysis
21 of the duodenum tissue was focused on enterocytes atrophy and cellular infiltration
22 determination in the analyzed tissue. No differences were found between treated and

1 control animals. Biochemical blood parameters analyzed in treated and control animals
2 serum did not show any significant differences between them (Table 3). Bile salts, GTP and
3 GOT showed lower values in treated than in control rats, but there were no statistically
4 significant differences between both animal groups. All biochemical parameters analyzed
5 were within the standard healthy range. This result supports the data reported in the
6 scientific literature describing that ENs inhibit the enzyme acyl-CoA:cholesterol
7 acyltransferase (ACAT) (Tomoda et al., 1992).

8 No adverse effect was observed in treated rats at the mycotoxin concentration used during
9 the 28 day treatment. The lack of toxic effects produced by ENs on the animal model
10 studied is in agreement with the data published by Bosch et al., (1989). The authors tested
11 the toxic effect of deoxynivalenol (DON), zearalananone (ZEA), moniliformin (MON),
12 fusaraneone-X (FX), 3-15 Acetyl-DON and ENs A, A₁, B, B₁ naturally present in
13 contaminated corn on twenty day-old white virgin female Sprague Dawley rats. During five
14 days, treated animals were fed with a 1:1 mixture of fermented *Fusarium* rice culture and
15 complete rat diet, whereas control rats received only complete rat diet. Surviving rats were
16 sacrificed by cervical dislocation and examined for gross pathological changes in the
17 tissues. To be certain of the ENs effects, they administered orally 2 mg of ENs mixture to
18 rats weighting 40 g approximately each. The observation lasted 5 days and no toxic signs
19 were found. This result is comparable with the data observed in our study.

20 Very scarce scientific literature related with *in vivo* toxic effects of ENs is available.
21 McKee et al. (1997) administrated intraperitoneally to mice ENs in a concentration range
22 from 1.25 to 40 mg/kg bw/8h during six days. The top three doses of the ENs mixture (40,
23 20, 10 mg/kg bw) tested in the hollow-fiber assay were toxic to all mice in the tested
24 groups. With the highest dose, most deaths occurred between days 2 and 3, while for the 20

1 and 10 mg/kg bw dose groups, deaths occurred between days 4 and 5. For all surviving
2 groups, there was a dose-dependent weight loss. These toxic effects indicated that a
3 maximum-tolerated dose for the ENs was achieved within the tested dose range.
4 Unfortunately, a comparison between the results reported by McKee et al. (1997) and those
5 reported in this study was not possible due to the different species assayed as well as the
6 different route of the toxin administration chosen. The use of solvents to dissolve
7 compounds to test is not the best approach to study any molecule toxicity *in vivo* due to the
8 response that the animals can have to the solvent. EN A oral administration of a naturally
9 contaminated rat feed was chosen for our approach in order to simulate a natural intake of
10 the compound studied. Usually, the bioactive compound administration in animal
11 experiments through alternative methodologies to the oral intake as intraperitoneal
12 injection, promotes the reaching of observed adverse effect levels due to the bypass of the
13 gastrointestinal digestion reaction that can influence the structure of the compound studied
14 (Jestoi, 2008). The last important point is the interaction between the compound studied
15 and the matrix effects generated by the other feed components. This phenomenon is absent
16 in the experiments carried out with standard solutions of toxic compounds intraperitoneally
17 injected as proven by McKee et al. (1997).

18 The EN A concentration was determined in several organs and biological fluids. Digesta
19 from stomach, duodenum, jejunum, ileum and colon were evaluated. The gastrointestinal
20 tract and the kidneys were also analyzed. The EN A chromatogram present in the liver
21 sample of a treated animal with the contaminated feed compared with the control rat is
22 shown in figure 3.

1 As exposed in figure 4a, the lowest EN A concentration was detected in colon and
2 duodenum with 2.2 ± 0.7 mg/kg and 2.9 ± 0.6 mg/kg respectively, probably because of a
3 weak absorption of the bioactive compound in those gastrointestinal tract parts. The highest
4 EN A concentration was observed in liver with 22.7 ± 1.0 mg/kg and it may be related to its
5 detoxification function of bioactive compounds transported from the intestine through the
6 portal vein and others present in the human body. The molecules transported are normally
7 accumulated into the hepatocytes where they are metabolized by the enzymes present in the
8 bile that can modify their chemical structure. Liver and kidneys are particularly susceptible
9 to organ toxicity as they are the sites of toxin filtration and toxin metabolic breakdown. The
10 secondary products produced by toxic compound metabolism can also be accumulated in
11 the liver and may be potentially toxic for the animal body (Kerns and Di, 2008). However,
12 no EN A was detected neither in kidneys, stomach nor ileum.

13 Regarding the intrainestinal liquids, the highest EN A data was observed in the jejunum
14 content with 9.6 ± 1.1 mg/kg, whereas the lowest in the duodenal liquid with 1.3 ± 0.2 mg/kg.
15 Significant EN A concentrations were measured in the colon content with 7.3 ± 0.7 mg/kg,
16 whereas the EN A data found in the gastric content and in serum were of 4.6 ± 0.2 and
17 5.0 ± 0.5 mg/kg respectively (Figure 4b). No EN A was observed in ileum content.

18 3.4 LC-MS-LIT determination of ENs degradation products

19 The gastrointestinal content extracts were also injected in the LC-MS-LIT to identify
20 possible degradation products produced through the gastrointestinal fermentation by gut
21 microflora. Two degradation products were detected in the duodenal compartment
22 represented by the EN A with the loss of an isoleucine (Ile) group, an aminoacid

1 characteristic of the ENs structure, and by the EN A with the loss of a hydroxivaleric acid
2 unit (HyLv). The concentration in duodenum digesta of these two degradation products was
3 of 89.7 ± 3.2 and of 123.55 ± 4.1 mg/L respectively. The presence of these newly formed
4 compounds was confirmed employing the technique of the LC-MS coupled to the LIT. As
5 explained in table 4 the structure of the degradation compound ENA-Ile was confirmed by
6 the fragment with $m/z = 577.1$ that represents the molecular weight (MW) of the compound
7 formed. By fragmentation of this signal, two diagnostic signals were obtained in MS^2 with
8 m/z of 547.3 represented by the EN A-Ile with the loss of a carbonyl group and m/z of
9 292.4, the EN A with the loss of two Ile group. The last confirmation of the structure of this
10 degradation product was obtained by the MS^3 spectra, where are evidenced the
11 characteristic fragments of the two principal ENs components as the Ile and HyLv. The
12 MS^1 fragment of the degradation product composed by the EN A with the HyLv group loss
13 presents a m/z of 637.4. The structure of this product formed was confirmed by the
14 fragments in MS^2 with m/z of 537.1 and MS^3 with m/z of 533.4. They represent the EN A
15 with the loss of four molecules of water and by the EN A with the loss of two HyLv units.
16 Definitive confirmation fragments in MS^3 were the signals with m/z of 84 represented by
17 one HyLv unit and 168.0, two HyLv units. The presence of this important EN A structural
18 component in MS^3 confirmed the structure of the degradation product formed.

19 The adducts formed between the EN A and the macronutrients present in rat feed detected
20 and characterized are described in table 5. In the duodenum and jejunum compartments was
21 detected the adduct formed with the EN A and two molecules of glucose. As shown in table
22 5, this newly formed compound presents a m/z of 1022.0. The structure of the bioactive
23 compound formed was confirmed by the fragments obtained in MS^2 and represented by the

1 signals with a m/z 937.3 and 916.3 that confirmed the loss by the structure of the adduct of
2 an EN A component as the HyLv. In MS^3 spectra was observed an important diagnostic
3 signal with m/z of 181.16 represented by the MW of a glucose unit. The concentrations
4 calculated for this newly formed compound in the duodenum and jejunum compartments
5 were 196.74 ± 6.3 and 149.39 ± 4.9 mg/L respectively.

6 Another important adduct detected in the duodenal compartment was the reaction product
7 originated by the reaction between the EN A and the glucuronic acid. Uridine diphosphate
8 glucuronosyltransferase (UDP-GT or UGT) is a family of inducible microsomal
9 isoenzymes associated with the liver, intestine, lung and olfactory epithelium. These
10 isozymes catalyze glucuronidation, the transfer of glucuronic acid from the high-energy
11 nucleotide UDP-glucuronic acid (UDP-GA) to an electronegative group on a wide variety
12 of endogenous and xenobiotic substrates (Hayes, W.A., 2007). The concentration found of
13 this adduct in the duodenal compartment was 121.98 ± 6.8 mg/L. The confirmation of the
14 adduct formed was carried out using the LC-MS coupled with the LIT operating in MS^1 ,
15 MS^2 and MS^3 . The ER spectra in MS^1 evidenced a diagnostic fragment with a m/z 112.3
16 that represents the EN A coupled with two units of glucuronic acid. The presence of that
17 compound was confirmed in the MS^2 spectra with a fragment with a m/z of 914.4. The final
18 confirmation of the coupling adduct obtained with the reaction between the EN A and the
19 glucuronic acid was evidenced in the MS^3 spectra whit the fragment corresponding to the
20 MW of the glucuronic acid with a m/z of 195.1.

21 Related to the adducts formed with EN A and macronutrients, in the colonic compartment
22 was detected the product of the reaction between the EN A and four glucose units. This
23 product was detected at the concentration of 42.02 ± 8.2 mg/L and presents in MS^1 spectra a

1 MW of 1517.8 g/mol. The presence of the glucose in the adduct structure was confirmed by
2 the localization of several fragments in the MS² spectra and, in particular, one fragment
3 present in the MS³ spectra with a m/z of 724.6, represented by four glucose units.

4 Among the adducts detected in several intestinal compartments, only the reaction product
5 between the EN A and two glucose units was found in serum. This compound can be
6 considered the only adduct detected in this study that was absorbed by the intestinal
7 epithelium and was detected in the rat blood (66.11±7.1 mg/L). The reasons for the
8 presence of this compound in the systemic circulation possibly because of the high
9 concentrations detected in the duodenum and jejunum compartment that favored the
10 absorption of the adduct formed. The structure of this adduct observed in serum was
11 confirmed by several diagnostic fragments as the ion detected in MS¹ spectra with a m/z of
12 1065.1 that represents the MW of the adduct, the signal detected in the MS² spectrum with
13 a m/z of 1013 represented by the adduct with the loss of an EN A structural component as
14 the Ile and, definitely, the presence of the ion with a m/z of 181.6 in the MS³ spectrum,
15 confirmed the glucose presence in the structure of the newly formed compound.

16 To sum up, EN A intestinal degradation products and adducts are described for the first
17 time. Further investigation is needed in order to fill the gap of the metabolic routes
18 affecting EN A.

19 **Conclusion**

20 The results obtained in this study confirmed that the EN A concentration of 20.91 mg/kg
21 bw/day present in rat feed through a microbial fermentation by a strain of *Fusarium*
22 *tricinctum*, used during 28 days on Wistar rats simulating a preliminar subchronic toxicity

1 study, does not provoke any observed adverse effect on the animals. No statistical
2 differences on the biochemical blood parameters or on the histological analysis carried out
3 on the duodenum tissue were found when comparing controls with treated animals. Thus,
4 we can confirm that 20.91 mg/ kg bw/day of EN A is a non-toxic level for young adult rats
5 during medium term ingestion.

6 EN A was detected in several organs and contents of the gastrointestinal tract, but also in
7 serum confirming its intestinal absorption. EN A degradation products and adducts,
8 probably produced by gut microbial fermentation, were identified and characterized.

9 It is presented for the first time experimental data of interest that give information about
10 toxicokinetic processes and potential effects after oral administration *in vivo* of emerging
11 mycotoxins that may be of interest to international institutions when conducting risk
12 evaluation assessment.

13 Further investigation may be focused on the calculation of the lowest-observed-adverse-
14 effect-level (LOAEL) for the ENs in order to establish a dose-response relationship, a
15 fundamental step to assess the risk related to the intake of these mycotoxins.

16 **Acknowledgments**

17 This research was supported by the Ministry of Science and Innovation (AGL2010-17024).
18 Y. Rodríguez-Carrasco thanks the FPU Grant (AP2010-2940) provided by the Ministry of
19 Education. A.B. Serrano thanks the FPI grant (BES-2011-045454) provided by the Ministry
20 of Science and Innovation. J. Tolosa thanks the Quality and Prevention of Food Hygiene in
21 Catering Services of the University of València.

22 **Declaration of interest**

1 The authors report no declarations of interest.

2 **References**

- 3 Akbas, Y., Pata, Y.S., Unal, M., Gorur, K., Micozkadioglu, D., 2004. The effect of
4 fusafungine on post-operative pain and wound healing after pediatric tonsillectomy.
5 *Int. J. Pediatr. Otorhinolaryngol.* 68, 1023-1026.
- 6 Behm, C., Degen, G.H., Follmann, W., 2009. The Fusarium toxin enniatin B exerts no
7 genotoxic activity, but pronounced cytotoxicity in vitro. *Mol. Nutr. Food Res.* 53,
8 423-430.
- 9 Bosch, U., Mirocha, C.J., Abbas, H.K., Dimenna, M., 1989. Toxicity and toxin production
10 by Fusarium isolates from New Zealand. *Mycopathologia* 108, 73-79.
- 11 Chelkowski, J., Ritieni, A., Wisniewska, H., Mule, G., Logrieco, A., 2007. Occurrence of
12 Toxic Hexadepsipeptides in Preharvest Maize Ear Rot Infected by Fusarium poae in
13 Poland. *Journal of Phytopathology.* 155, 8-10.
- 14 De la Luz, M., Chiericatti, C., Aringoli, E., Althaus, R.L., Basílico, J.C., 2007. Influence of
15 environmental factors on airborne fungi in houses in Santa Fe City, Argentina. *Sci.*
16 *Total Environ.* 376, 143-150.
- 17 Dornetshuber, R., Heffeter, P., Lemmens-Gruber, R., Elbling, L., Marko, D., Micksche, M.,
18 Berger, W., 2009. Oxidative stress and DNA interactions are not involved in enniatin-
19 and beauvericin-mediated apoptosis induction. *Mol. Nutr. Food Res.* 53, 1112–
20 1122. enniatin B. *Anal. Bioanal. Chem.* 400, 2889-2901.
- 21 Faeste, C.K., Ivanova, L., Uhlig, S., 2011. In Vitro Metabolism of the Mycotoxin Enniatin
22 B in Different Species and Cytochrome P450 Enzyme Phenotyping by Chemical
23 Inhibitors. *Am. Soc. For Pharmacol. Experi. Therap.* 39, 1768-1776.
- 24 Fornelli, F., Minervini, F., Logrieco, A., 2004. Cytotoxicity of fungal metabolites to
25 lepidopteran (*Spodoptera frugiperda*) cell line (SF 9). *J. Invertebr. Pathol.* 85, 74-79.
- 26 Guengerich, F.P., 2001. Common and uncommon cytochrome P450 reactions related to
27 metabolism and chemical toxicity. *Chem. Res. Toxicol.* 14, 611-650.
- 28 Hayes, W.A. 2007. Principles and techniques of toxicology. 5th Ed. 39, 1924-1965.
- 29 Hyun, U., Lee, D.H., Lee, C., Shin, C.G., 2009. Apoptosis induced by enniatins H and
30 MK1688 isolated from *Fusarium oxysporum* FB1501. *Toxicon* 53, 723-728.
- 31 Ivanova, L., Eystein Skjerve, E., Eriksen, G.S., Uhlig, S., 2006. Cytotoxicity of enniatins
32 A, A1, B, B1, B2 and B3 from *Fusarium avenaceum*. *Toxicon*, 2006, 47, 868-876.
- 33 Ivanova, L., Uhlig, S., Eriksen, G.S., Johannessen, L.E., 2011. In vitro phase I metabolism
34 of the depsipeptide enniatin B. *World Mycotox. J.* 3, 271-281.

- 1 Jestoi, M., 2008. Emerging Fusarium-mycotoxins fusaproliferin, beauvericin, enniatins, and
2 moniliformin. A review. Crit. Rev. Food Sci. Nutr. 48, 21-49.
- 3 Kelly, S., Grimm, L.H., Bendig, C., Hempel, D.C., Krull, R., 2006. Effects of fluid
4 dynamic induced shear stress on fungal growth and morphology. Process. Biochem.
5 41, 2113-2117.
- 6 Kers, E., Di, L., 2008. Drug like properties: Concepts, structure design and methods, from
7 the ADME to toxicity optimization. Elsevier Inc. pp 28-29.
- 8 Lane RW and Borzelleca JF. 2008. Principles and methods of toxicology. CRC Press. pp 3-
9 44.
- 10 Lee, H.S., Song, H.H., Jeong, J.H., Shin, C.G., Choi, S.U., Lee, C., 2008. Cytotoxicities of
11 enniatins H, I, and MK1688 from *Fusarium oxysporum* KFCC 11363P. Toxicon 51,
12 1178-1185.
- 13 McKee, T.C., Bokesch, H.R., McCormick, J.L., Rashid, M.A., Spielvogel, D., Gustafson,
14 K.R., Alavanja, M.M., Cardellina, J.H., Boyd, M.R., 1997. Isolation and
15 characterization of new anti-HIV and cytotoxic leads from plants, marine and
16 microbial origins. J. Nat. Prod. 60, 431-438.
- 17 Meca, G., Zinedine, A., Blesa, J., Font, G., Mañes, J., 2010a. Further data on the presence
18 of Fusarium emerging mycotoxins enniatins, fusaproliferin and beauvericin in cereals
19 available on the Spanish markets. Food Chem. Toxicol. 48, 1412-1416.
- 20 Meca, G., Ruiz, M.J., Soriano, J.M., Ritieni, A., Moretti, A., Font, G., Mañes, J., 2010b.
21 Isolation and purification of enniatins A, A1, B, B1, produced by *Fusarium tricinctum*
22 in solid culture, and cytotoxicity effects on Caco-2 cells. Toxicon 56, 418-424.
- 23 Meca, G., Font, G., Ruiz, M.J., 2011. Comparative cytotoxicity study of enniatins A, A1,
24 A2, B, B1, B4 and J3 on Caco-2 cells, Hep-G2 and HT-29. Toxicon 49, 2464-2469.
- 25 Meca, G., Meneghelli, G., Ritieni, A., Mañes, J., 2012. G. Font Influence of different
26 soluble dietary fibers on the bioaccessibility of the minor Fusarium mycotoxin
27 beauvericin. Food Chem. Toxicol. 50, 1362-1368.
- 28 R., Fogliano, V., 1997. Occurrence of fusaproliferin, fumosinin B1 and beauvericin in
29 maize from Italy. J. Agric. Food Chem. 45, 4011-4016.
- 30 Smith, D.A., Obach, R.S., 2009. Metabolites in safety testing (MIST): considerations of
31 mechanisms of toxicity with dose, abundance, and duration of treatment. Chem Res
32 Toxicol 22, 267-279.
- 33 Supothina, S., Isaka, M., Kirtikara, K., Tanticharoen, Thebtaranonth, M.Y., 2004. Enniatin
34 Production by the Entomopathogenic Fungus *Verticillium hemipterigenum* BCC
35 1449. J. Antibiot. 57, 732-738.

1 Thompson, M., Ellison, S., Fajgelj, A., Willetts, P., Wood, R. Harmonized guidelines for
2 the use of recovery information in analytical measurement. *Pure & Appl. Chem.*
3 (1999) 71(2), 337–348.

4 Tomoda H., Huang X.H., Cao J., Nishida H., Nagao R., Okuda S., Tanaka H., Omura S.,
5 Arai H., Inoue K. Inhibition of acyl-CoA: cholesterol acyltransferase activity by
6 cyclodepsipeptide antibiotics. *J. Antibiot. (Tokyo)*, 45 (1992), 1626–1632

7 Tonshin, A.A., Teplova, V.V., M.A., Andersson, Salkinoja-Salonen, M.S., 2010. The
8 *Fusarium* mycotoxins enniatins and beauvericin cause mitochondrial dysfunction by
9 affecting the mitochondrial volume regulation, oxidative phosphorylation and ion
10 homeostasis. *Toxicology* 276, 49-57.

11 Vongvilai, P., Isaka, M., Kittakoop, P., Srikitikulchai, P., Kongsaree, P., Prabpai, S.,
12 Thebtaranonth, Y., 2004. Isolation and structure elucidation of enniatins L, M-1, M-2,
13 and N: Novel hydroxy analogs. *Helv. Chem. Acta* 87, 2066-2073.

14 Watjen, W., Debbab, A., Hohlfeld, A., Chovolou, Y., Kampkotter, A., Edrada, R.A., Ebel,
15 R., Hakiki, A., Mosaddak, M., Totzke, F., Kubbutat, M. H.G., Proksch, P., 2009.
16 Enniatins A1, B and B1 from an endophytic strain of *Fusarium tricinctum* induce
17 apoptotic cell death in H4IIE hepatoma cells accompanied by inhibition of ERK
18 phosphorylation. *Mol. Nutr. Food Res.* 53, 431-440.

19 Zhukhlistova, N.E., Tishchenko, G.N, Tolstykh, I.V., Zenkova, V.A., 1999. X-ray crystal
20 structure of the complex of enniatin B with KNCS. *Crystallogr. Rep.* 44, 8-12.

21
22
23
24
25
26
27
28
29
30
31
32

1 **Legend of figures**

2 **Figure 1.** Schematic representation of the *in vivo* study carried out on EN A toxicity.

3 **Figure 2.** a) LC-MS-LIT chromatogram of the EN A present in the feed contaminated with
4 the strain of *Fusarium tricinctum* CECT 20232 and b) mass spectrum in linear ion trap
5 (MS-LIT) of the EN A.


6 **Figure 3.** a) LC-DAD chromatogram of the ENA present in the liver of the rat treated with
7 the feed contaminated with the EN A, compared with b) the liver of the control animals.

8 **Figure 4.** EN A concentration detected by LC-DAD in organs, gastrointestinal liquids and
9 serum of treated female rats (n=5). Their diet consisted in EN A contaminated feed (465
10 mg/kg) *ad libitum* during 28 days. Control rats (n=5) ate standard feed and no trace of EN
11 A was detected during the whole analysis in any sample. a) Different organs from treated
12 rats. b) Mycotoxin concentration present in the gastrointestinal liquids and serum of treated
13 animals.

14 **Figure 5.** Quantification of the a) EN A degradation products originated by the microbial
15 fermentation of the ENA present in the rat feed by the intestinal microflora and b) adducts
16 of formation of the EN A with the glucose in the liquid of several intestinal compartments.
17 Ile: isoleucine. HyLv: hydroxivaleric acid. Duod: duodenum. Gluc. Ac.: glucuronic acid.
18 Glu: glucose. Col: colon.

19 **Figure 6.** LC-MS-LIT chromatogram of the EN A and of the adduct of formation between
20 the minor *Fusarium* mycotoxin and the glucose evidenced in the serum of treated animals.
21 Glu: glucose.

1



2

3

4

5

6

7

8



9



10

11

12


13








- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9

4. a




4. b





1



2

Table 1. EN A mean recoveries, inter-day and intra-day variations, limit of detection (LOD) and limit of quantitation (LOQ) of the analytical method applied to the different matrices analyzed in this study in which EN A has been detected.

<i>Sample</i>	<i>Mean recovery (%)</i>	<i>Inter-day variation (%)</i>	<i>Intra-day variation (%)</i>	<i>LOD (mg/Kg)</i>	<i>LOQ (mg/Kg)</i>
<i>Gastric content</i>	156.3±1.5	2.0	8.7	0.2	0.6
<i>Duodenum content</i>	97.2±3.4	2.2	9.6	0.2	0.6
<i>Duodenum</i>	97.1±2.6	2.5	9.2	0.2	0.6
<i>Jejunum content</i>	98.2±3.4	2.5	7.5	0.2	0.6
<i>Jejunum</i>	97.5±2.0	3.1	10.2	0.2	0.6
<i>Colon content</i>	70.2±2.2	2.4	8.8	0.2	0.6
<i>Colon</i>	71.4±3.1	2.0	9.6	0.2	0.6
<i>Liver</i>	93.1±2.0	2.6	9.1	0.2	0.6
<i>Serum</i>	100.0±2.8	2.4	8.6	0.2	0.6

Table 2. a) Weekly body weight measurements during the study of the rats used. At week 0, first day of the 28 day-study b) Comparison of organs weight of these rats measured at terminal sacrifice.

a)

	BODY WEIGHT (g)									
	CONTROL RATS					TREATED RATS				
	1	2	3	4	5	1	2	3	4	5
Week 0	242.0	269.8	289.2	229.0	236.4	268.8	261.4	252.6	236.6	255.4
Week 1	244.6	273.2	295.2	228.4	244.6	262.4	255.8	256.2	233.0	248.2
Week 2	252.0	274.0	296.0	229.0	250.0	272.2	269.8	253.8	234.8	259.2
Week 3	253.4	290.0	270.8	227.6	252.2	279.6	274.6	265.2	230.2	267.8
Week 4	255.4	285.3	262.6	230.3	257.1	284.4	270.2	268.1	222.3	274.3

b)

	ORGAN WEIGHT (g)									
	CONTROL RATS					TREATED RATS				
	1	2	3	4	5	1	2	3	4	5
Liver	8.40	9.31	9.82	8.07	7.61	7.54	8.12	7.43	7.15	7.58
Kidneys	1.61	1.85	1.59	1.41	1.36	1.53	1.66	1.46	1.59	1.63
Heart	0.84	0.97	1.03	0.72	0.92	0.92	0.89	0.97	0.93	0.78
Thymus	0.53	0.53	1.02	0.43	0.53	0.62	0.55	0.56	0.51	0.79
Spleen	0.42	0.51	0.50	0.38	0.46	0.57	0.54	0.55	0.50	0.63

Table 3. Biochemical parameters analyzed in control (n=5) and treated (n=5) rat serum. GPT=glutamic-pyruvic transaminase, GOT=glutamic-oxaloacetic transaminase, γ -GT=gamma-glutamyl transpeptidase.

Samples	Bile salts $\mu\text{mol/L}$	GPT U/L	GOT U/L	Total bilirubin mg/dL	Cholesterol mg/dL	Alkaline phosphatase U/dL	γ-GT U/L	Urea mg/dL
Controls rats	47.6 \pm 3.1	41.2 \pm 3.9	98.2 \pm 9.7	0.1 \pm 0.05	92.6 \pm 9.6	71.5 \pm 7.1	<5	42.6 \pm 3.5
Treated rats	28.5 \pm 3.2	28.4 \pm 3.9	84.8 \pm 9.8	0.1 \pm 0.03	85.6 \pm 8.7	68.8 \pm 8.6	<5	47.2 \pm 5.4

Table 4. EN A intestinal degradation products. Two degradation products from ENN A found in the intestinal compartment of the treated rats, in which compartment where they were discovered and their MS¹, MS² and MS³ fragments.







Degradation product	Biological liquid	[M+H] ⁺ m/z	Fragment	Structure	MS ² fragments		MS ³ fragments	
					m/z	Fragment	m/z	Fragment
(EN A+K-Ile) ⁺	Duodenum	577.1	Ile		547.3	(EN A+K-Ile-C=O) ⁺	85.0	(HyLv) ⁺
	Colon				292.4	(EN A+K-2Ile) ⁺	144.2	(Ile) ⁺
(EN A+K-HyLv) ⁺	Duodenum	637.4	HyLv		537.1	(EN A+K-4H2O) ⁺	84.0	(HyLv) ⁺
	Colon				533.4	(EN A+K-2HyLv) ⁺	168.0	2(HyLv) ⁺

Table 5. ENN A intestinal adducts. Four adducts formed with ENN A and macronutrients present in the rats feed, in which compartment where they were discovered and their MS¹, MS² and MS³ fragments.

Adducts	Biological liquid	[M+H] ⁺ m/z	Adduct Fragment	Structure	MS ² fragments		MS ³ fragments	
					m/z	Fragment	m/z	Fragment
(EN A+2Glu-H ₂ O) ⁺	Duodenum	1022.0	Glu		937.3	(EN A+2Glu-H ₂ O-HyLv) ⁺	181.16	(Glu) ⁺
	Jejunum				916.3	(EN A+2Glu-2H ₂ O-HyLv) ⁺	84.0	(HyLv) ⁺
(EN A+K+4Glu) ⁺	Colon	1517.8	Glu		1442.4	(EN A+K+4Glu-HyLv) ⁺	84.0	(HyLv) ⁺
					1373.8	(EN A+K+4Glu-HyLv-Ile) ⁺	144.2	(Ile) ⁺
					1042.4	(EN A+K+4Glu-HyLv-3Ile-2H ₂ O) ⁺	724.6	4(Glu) ⁺
(EN A+2Gluc Ac.) ⁺	Duodenum	1112.3	Gluc Ac.		914.4	(EN A+Gluc Ac.) ⁺	195.1	(Gluc Ac.) ⁺
							390.2	2(Gluc Ac.) ⁺
(EN A+Na+2Glu) ⁺	Serum	1065.1	Glu		903.9	(EN A+Na+2Glu-Ile-H ₂ O) ⁺	181.16	(Glu) ⁺